Lantern Pharma Inc.
LTRN
$2.51
$0.4521.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.39% | 30.75% | 4.20% | 1.95% | 24.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.72% | -16.02% | -13.99% | -16.71% | 20.89% |
| Operating Income | 28.72% | 16.02% | 13.99% | 16.71% | -20.89% |
| Income Before Tax | 30.65% | 7.29% | 12.67% | 16.62% | -40.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.65% | 7.29% | 12.67% | 16.62% | -40.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.65% | 7.29% | 12.67% | 16.62% | -40.36% |
| EBIT | 28.72% | 16.02% | 13.99% | 16.71% | -20.89% |
| EBITDA | 28.74% | 16.03% | 14.00% | 16.73% | -20.90% |
| EPS Basic | 32.57% | 7.88% | 12.89% | 16.94% | -38.46% |
| Normalized Basic EPS | 31.91% | 7.87% | 12.88% | 14.24% | -36.32% |
| EPS Diluted | 32.57% | 7.88% | 12.89% | 16.94% | -38.46% |
| Normalized Diluted EPS | 31.91% | 7.87% | 12.88% | 14.24% | -36.32% |
| Average Basic Shares Outstanding | -- | 0.65% | 0.24% | 0.39% | 1.37% |
| Average Diluted Shares Outstanding | -0.43% | 0.65% | 0.24% | 0.39% | 1.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |